1-(2,6-difluorophenyl)-3-[6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl]urea | 320363-44-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-(2,6-difluorophenyl)-3-[6-methoxy-7-(3-morpholinopropoxy)quinazolin-4-yl]urea
• 英文别名: 1-(2,6-Difluorophenyl)-3-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-yl]urea
• CAS: 320363-44-8
• 化学式: C₂₃H₂₅F₂N₅O₄
• 分子量: 473.479
• InChiKey: KSNTYYGPIMDEGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  97.8
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• QUINAZOLINE DERIVATIVES
  申请人：AstraZeneca UK Limited

  公开号：EP1218353A1

  公开（公告）日：2002-07-03
• US6806274B1
  申请人：——

  公开号：US6806274B1

  公开（公告）日：2004-10-19
• [EN] QUINAZOLINE DERIVATIVES<br/>[FR] DERIVES DE QUINAZOLINE
  申请人：ASTRAZENECA UK LTD

  公开号：WO2001004102A1

  公开（公告）日：2001-01-18

  The invention concerns quinazoline derivatives of Formula (I) wherein Q1 includes a quinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q3-X1- wherein X1 includes a direct bond and O and Q3 includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of R?2 and R3¿ is hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Q2 includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal.
• [EN] QUINAZOLINES WITH THERAPEUTIC USE<br/>[FR] QUINAZOLINES A USAGE THERAPEUTIQUE
  申请人：ASTRAZENECA AB

  公开号：WO2002002534A1

  公开（公告）日：2002-01-10

  The invention concerns the use of quinazoline derivatives of Formula (I) wherein Q1 includes a qinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q3-X1- wherein X1 includes a direct bond and O and Q3 includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6)alkyl; each of R?2 and R3¿ is hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Q2 includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof; in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.